All In Biotech

Drug Trial Radar · NCT07754825

A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of LT3001 in Participants With Acute Ischemic Stroke (AIS)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke

Conditions

  • Acute Ischemic Stroke

Interventions

  • LT3001 Drug:high doseDrug

    Drug: LT3001 Drug:high dose Administered by intravenous infusion.

  • LT3001 Drug: low doseDrug

    Drug: LT3001 Drug: low dose Administered by intravenous infusion.

  • PlaceboDrug

    Drug: Placebo Administered by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants by mRS(Modified Rankin Scale) score (0 - 1)Time frame: Day 90 after the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.